The emerging evidence for Stereotactic Body Radiotherapy

Acta Oncologica

Volumn 45, Issue 7, 2006, Pages 771-774

  Grau, Cai ^a   Høyer, Morten ^a   Lindegaard, Jacob ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AXILLARY LYMPH NODE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; STEREOTAXIS;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; RADIATION DOSAGE; RADIOSURGERY; SURGERY, COMPUTER-ASSISTED;

EID: 33748867973     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600943290     Document Type: Conference Paper

References (56)

1. Overgaard J. Management of the axilla in breast cancer. Implication for diagnosis, prognosis, treatment, and morbidity. Acta Oncol 2000;39:259-60.
2. Levitt S. Second Acta Oncologia symposium on prostate cancer controversies. Acta Oncol 2005;44:526-8.
3. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.
4. Wahlgren T, Nilsson S, Ryberg M, Lennernas B, Brandberg Y. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta Oncol 2005;44:633-43.
5. Grabe M, Bjartell A, Wullt B. PROQUR: A tool for quality control, epidemiological surveillance, patient follow-up and clinical research activities related to prostate cancer. Acta Oncol 2005;44:628-32.
6. Essand M. Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies. Acta Oncol 2005;44: 610-27.
7. Damber JE. Endocrine therapy for prostate cancer. Acta Oncol 2005;44:605-9.
8. Damber JE, Khatami A. Surgical treatment of localized prostate cancer. Acta Oncol 2005;44:599-604.
9. Borre M, Lundorf E, Marcussen N, Langkilde NC, Wolf H. Phased array magnetic resonance imaging for staging clinically localised prostrate cancer. Acta Oncol 2005;44:589-92.
10. Hedestig O, Sandman PO, Tomic R, Widmark A. Living after radical prostatectomy for localized prostate cancer: A qualitative analysis of patient narratives. Acta Oncol 2005; 44:679-86.
11. Incrocci L. Radiation therapy for prostate cancer and erectile (dys)function: The role of imaging. Acta Oncol 2005;44: 673-8.
12. Malmstrom PU. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005;44:593-8.
13. Lax I. Target dose versus extratarget dose in stereotactic radiosurgery. Acta Oncol 1993;32:453-7.
14. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861-70.
15. Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994;33:677-83.
16. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005;76:48-53.
17. Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005;77:88-95.
18. Traberg Hansen A, Petersen JB, Hoyer M, Christensen JJ. Comparison of two dose calculation methods applied to extracranial stereotactic radiotherapy treatment planning. Radiother Oncol 2005;77:96-8.
19. Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 2006;45:493-7.
20. Dahl O. Protons. A step forward or perhaps only more expensive radiation therapy? Acta Oncol 2005;44:798-800.
21. Goitein M, Goitein G. Swedish protons. Acta Oncol 2005; 44:793-7.
22. Glimelius B, Ask A, Bjelkengren G, Bjork-Eriksson T, Blomquist E, Johansson B, et al. Number of patients potentially eligible for proton therapy. Acta Oncol 2005;44: 836-49.
23. Bjork-Eriksson T, Ask A, Glimelius B. The potential of proton beam radiation for palliation and reirradiation. Acta Oncol 2005;44:918-20.
24. Bjork-Eriksson T, Bjelkengren G, Glimelius B. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma. Acta Oncol 2005;44:913-7.
25. Ask A, Johansson B, Glimelius B. The potential of proton beam radiation therapy in gastrointestinal cancer. Acta Oncol 2005;44:896-903.
26. Johansson B, Ridderheim M, Glimelius B. The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers. Acta Oncol 2005;44:890-5.
27. Bjork-Eriksson T, Glimelius B. The potential of proton beam radiation therapy in breast cancer. Acta Oncol 2005; 44:884-9.
28. Bjelkengren G, Glimelius B. The potential of proton beam radiation therapy in lung cancer (including mesothelioma). Acta Oncol 2005;44:881-3.
29. Ask A, Bjork-Eriksson T, Zackrisson B, Blomquist E, Glimelius B. The potential of proton beam radiation therapy in head and neck cancer. Acta Oncol 2005;44:876-80.
30. Bjork-Eriksson T, Glimelius B. The potential of proton beam therapy in paediatric cancer. Acta Oncol 2005;44: 871-5.
31. Blomquist E, Bjelkengren G, Glimelius B. The potential of proton beam radiation therapy in intracranial and ocular tumours. Acta Oncol 2005;44:862-70.
32. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Proton therapy of cancer: Potential clinical advantages and cost-effectiveness. Acta Oncol 2005;44:850-61.
33. Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol 2003;42:123-36.
34. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181: 483-99.
35. Lavrenkov K, Partridge M, Cook G, Brada M. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 2005;77:1-4.
36. Hara R, Itami J, Kondo T, Aruga T, Abe Y, Ito M, et al. Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol 2002;63:159-63.
37. van Sornsen de Koste JR, Lagerwaard FJ, Schuchhard-Schipper RH, Nijssen-Visser MR, Voet PW, Oei SS, et al. Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer-an analysis of data generated using 'slow' CT scans. Radiother Oncol 2001;61: 93-9.
38. Dawson LA, Balter JM. Interventions to reduce organ motion effects in radiation delivery. Semin Radiat Oncol 2004;14:76-80.
39. Jaffray DA. Emergent technologies for 3-Dimensional image-guided radiation delivery. Sem Radiat Oncol 2005;15: 208-16.
40. Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980;6:41-4.
41. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: A clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986;12:867-72.
42. Bentzen SM, Overgaard J, Thames HD, Overgaard M, Vejby Hansen P, von der Maase H, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 1989;16:169-82.
43. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003;42:476-92.
44. Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M, et al. Cosmetic outcome and breast morbidity in breast-conserving treatment-results from the Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol 2002;41:369-80.
45. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: Long-term results of a randomised trial. Radiother Oncol 2005;75:9-17.
46. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005; 44:265-76.
47. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really? Radiother Oncol 2005;76:1-3.
48. Horsman MR, Khalil AA, Siemann DW, Grau C, Hill SA, Lynch EM, et al. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys 1994;29:439-42.
49. Brahme A, Nilsson J, Belkic D. Biologically optimized radiation therapy. Acta Oncol 2001;40:725-34.
50. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, et al. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
51. Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 2004;43:396-403.
52. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77:18-24.
53. Overgaard J. Sensitization of hypoxic tumour cells-clinical experience. Int J Radiat Biol 1989;56:801-11.
54. Horsman MR, Hoyer M, Honess DJ, Dennis IF, Overgaard J. Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy. Radiother Oncol 1993;27:131-9.
55. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994;6:509-18.
56. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Sem Radiat Oncol 1996;6:10-21.